Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Inhalational anthrax caused by Bacillus anthracis , a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demo...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	mSphere Ročník 4; číslo 3; s. e00282 - 19
Hlavní autori:	Tournier, Jean-Nicolas, Rougeaux, Clémence, Biot, Fabrice V., Goossens, Pierre L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Society for Microbiology 19.06.2019
Predmet:	Animal models Animals Anthrax Anthrax - immunology Anthrax - therapy Antibiotics Antibodies Antibodies, Bacterial Antibodies, Bacterial - therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Antigens Antigens, Bacterial Antigens, Bacterial - immunology Antitoxins Antitoxins - therapeutic use Bacillus anthracis Bacillus anthracis - immunology Bacterial Toxins Bacterial Toxins - immunology Disease Models, Animal Drug Evaluation, Preclinical Edema Humans Immunoglobulins Immunotherapy Infections Kinases Life Sciences Monoclonal antibodies Opinion/Hypothesis Patients Protective antigen Respiratory Tract Infections Respiratory Tract Infections - immunology Respiratory Tract Infections - therapy Sepsis Studies Therapeutics and Prevention Toxins Vaccines France United States > US antitoxins anthrax protective antigen toxins monoclonal antibodies
ISSN:	2379-5042, 2379-5042
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Inhalational anthrax caused by Bacillus anthracis , a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. Inhalational anthrax caused by Bacillus anthracis , a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 PMCID: PMC6584371 Citation Tournier J-N, Rougeaux C, Biot FV, Goossens PL. 2019. Questionable efficacy of therapeutic antibodies in the treatment of anthrax. mSphere 4:e00282-19. https://doi.org/10.1128/mSphere.00282-19.
ISSN:	2379-5042 2379-5042
DOI:	10.1128/mSphere.00282-19